Immune Response in Desensitized Patients (DELIGHT)
Impact of Desensitization Therapies on the Immune Response of Highly Sensitized Patients Awaiting Kidney Transplantation
Kidney transplantation is the best treatment for chronic renal failure in terms of morbidity and mortality, quality of life for patients and health economics. Sensitization with anti-Human Leukocyte Antigen antibodies is a barrier to access to transplantation.
Highly-sensitized patients wait 2 to 3 times longer on the waiting list with important health and economic consequences. Desensitization strategies by apheresis techniques allow access to a transplant with a negative crossmatch (absence of specific HLA antibodies against their donor) on the day of the transplant.
The main objective of this study is to assess the impact of desensitization on the antibody memory immune response in highly sensitized patients awaiting kidney transplantation.
The analyses will be based on samples from the 20 patients (10 desensitized transplanted patients, 5 highly sensitized non-desensitized transplanted patients and 5 healthy donors) at the University Hospital of Grenoble, France.
Analyses will include phenotypic and immuno-metabolic analysis by flow cytometry of antibody-secreting cells, a functional analysis by anti HLA ELISpot B technique and histological analysis of post-kidney transplantation follow-up renal biopsies with gene expression mapping (RNA tissue labeling using the Nanostring technique) within the renal parenchyma.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
15 highly sensitized patients: 10 that received desensitization before kidney transplan tation and 5 that were not desensitized before kidney transplantation.
5 healthy donors
Description
Inclusion Criteria:
- Adult patients (age >18 years) with end-stage renal disease (on hemodialysis or peritoneal dialysis or stage V chronic kidney disease) who are candidates for pre-renal transplantation desensitization from living or deceased donors.
- For women of childbearing age: a plasma pregnancy test before inclusion is mandatory. Highly effective contraception for women of childbearing age is required throughout the study period:
- combined hormonal contraception (containing estrogen and progestin)
contraception associated with ovulation inhibition :
- oral
- intravaginal
- transdermal
Progestin-only hormonal contraception associated with ovulation inhibition:
- oral
- injectable
- implantable
- intrauterine device (IUD) - intrauterine hormone delivery system (IUS)
- bilateral tubal occlusion
- vasectomized partner
- sexual abstinence
- Have signed the DELIGHT protocol consent.
- Affiliated to a social security system
- Can be contacted in case of emergency
- For the control groups :
- Healthy controls from blood samples (centrifugation ring) from the French Blood Agency. The use of healthy controls is necessary to compare immunological analyses to a reference group without immunosuppression.
- Highly sensitized kidney transplant patients without the need for de-immunization. Hyperimmunization is defined by a Panel Reactive Antibody score > 85%. Transplantation can be from deceased or living donors.
Exclusion Criteria:
- Patients who object to the use of their data and/or samples in the research
- Patients having received an immunosuppressive treatment in the 12 months preceding the inclusion
- All protected persons: pregnant women, parturients, nursing mothers, persons deprived of liberty by judicial or administrative decision, persons under legal protection.
- Subjects in a period of exclusion from another study
- Subject under administrative or judicial supervision
- Subject unable to be contacted in case of emergency
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Highly sensitized and desensitized kidney transplanted group
Patient that were HLA desensitized for kidney transplantation
|
Patients that received apheresis and anti-cluster of differentiation antigen 20 for desensitization priori to kidney transplantation
|
|
Highly sensitized and non-desensitized kidney transplanted group
Patient that were not HLA desensitized for kidney transplantation but were highly sensitized and received a kidney graft due to local priority system
|
|
|
Healthy donors
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Flow Cytometry analyses of Peripheral Blood Mononuclear Cells
Time Frame: Before desensitization, at the time of transplantation and Before desensitization, at the time of transplantation and post transplantation
|
Change of the percentage of "antibody secreting cells" (plasmablasts) over time
|
Before desensitization, at the time of transplantation and Before desensitization, at the time of transplantation and post transplantation
|
|
Change in Anti HLA B-cell ELISpot response
Time Frame: Before desensitization, at the time of transplantation and Month 3, Month 6 and Month 12 post transplantation
|
Change in the number of Spot over time
|
Before desensitization, at the time of transplantation and Month 3, Month 6 and Month 12 post transplantation
|
|
Change in Flow Cytometry analyses of medullary cells
Time Frame: The first day of desensitization and at the day of kidney transplantation
|
Change in the percentage of "antibody secreting cells" (plasmablasts) over time
|
The first day of desensitization and at the day of kidney transplantation
|
|
Change in analyses of RNA expression on renal histology
Time Frame: Month1, Month 3 and Month 12 post transplantation
|
CHange in percentage of gene expression using Nanostring technology
|
Month1, Month 3 and Month 12 post transplantation
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2022-A02445-38
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.